Company: SHPH
Filing Date: 2025-03-31
Form Type: DEF 14A
Source: 0001641172-25-001889
Chunk: 3

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-03-31
Form: DEF 14A
Chunk 3
---
 has been appointed as interim Chief Executive Officer,
focused on enhancing capital markets and business capabilities. Christopher brings a wealth of business experience which, when balanced
with the inherent scientific expertise of the Shuttle Pharma team, should allow for a more effective executive structure to inspire confidence
going forward.

We have also appointed
three new members to our board of directors (George Scorsis, Oleh Nabyt and Joseph Tung), offering business and legal backgrounds to help guide the Company going forward. In connection with appointments of new members, Dr. Milton
Brown, Dr. Chris Senanayake, Dr. Bette Jacobs and Mr. Joshua Schafer resigned from their positions. I personally thank Drs. Brown, Senanayake,
Jacobs and Mr. Schafer for their contributions to the company.

As a pre-revenue discovery
and developmental company, we are dependent on expanding our access to the capital markets, and most recently, we completed a $5.75 million
straight common stock offering in March 2025 to support the Phase 2 clinical trial for Ropidoxuridine and RT, for marketing and advertising
services, and for working capital and general corporate purposes.

OUR WORK. OUR PURPOSE.

At Shuttle Pharma, our mission is to launch the next generation of drugs to improve outcomes and achieve more cures for cancer patients undergoing
radiation treatments. We acknowledge that this will not be an easy task and will require dedication, extreme effort, and expertise.

Through teamwork and
strategic collaboration, we believe in our ability to make a meaningful difference in the lives of cancer patients. By pushing scientific boundaries and working together, we aim to
improve the lives of millions impacted by cancer and bring hope to patients and families around the world.

I thank our team and investors for continued support as Shuttle Pharma’s drugs achieve scientific milestones on a path
to commercialization and clinical application.

Sincerely yours,

/s/ Anatoly Dritschilo

Anatoly Dritschilo,
MD
Chairman of the Board of Directors

Shuttle Pharmaceuticals Holdings, Inc.

Notice of Annual Meeting of Stockholders of Shuttle Pharmaceuticals Holdings, Inc.

| ITEMS                                                                                                                            
 OF BUSINESS                                                                                                                      
 Proposal                                                                                                                         
 No. 1: Elect five (5) directors named in the attached Proxy Statement to serve until the 2026 Annual Meeting of Stockholders.    
 Proposal                                                                                                                         
 No. 2: To ratify appointment of Forvis Mazars, LLP as the Company’s independent auditor for the fiscal year